Jazz Pharmaceuticals Wins FDA Approval for Ziihera Regimens in First-Line HER2+ Advanced GEA

yf_tkr_JAZZ · 2026-08-25

$JAZZ

Jazz Pharmaceuticals (NASDAQ:JAZZ) has secured FDA approval for two Ziihera-containing regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma, expanding the drug into an earlier treatment setting after Phase 3 data showed improvements in progression-free and overall survival. Key Investor TakeawaysThe FDA approved Ziihera plus tislelizumab and chemotherapy for first-line treatment of HER2+ advanced GEA patients with IHC 3+ or IHC 2+/ISH+ disease, regardless of PD-L1 status

Read the original at yf_tkr_JAZZ ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.